key: cord-0997793-5vctyfe8
authors: Kreutmair, Stefanie; Unger, Susanne; Núñez, Nicolás Gonzalo; Ingelfinger, Florian; Alberti, Chiara; De Feo, Donatella; Krishnarajah, Sinduya; Kauffmann, Manuel; Friebel, Ekaterina; Babaei, Sepideh; Gaborit, Benjamin; Lutz, Mirjam; Jurado, Nicole Puertas; Malek, Nisar P.; Goepel, Siri; Rosenberger, Peter; Häberle, Helene A.; Ayoub, Ikram; Al-Hajj, Sally; Nilsson, Jakob; Classen, Manfred; Liblau, Roland; Martin-Blondel, Guillaume; Bitzer, Michael; Roquilly, Antoine; Becher, Burkhard
title: Distinct immunological signatures discriminate severe COVID-19 from non-SARS-CoV-2-driven critical pneumonia
date: 2021-05-09
journal: Immunity
DOI: 10.1016/j.immuni.2021.05.002
sha: 3e9cebd42a3e367e58c6cd2472175ddf22f14ae4
doc_id: 997793
cord_uid: 5vctyfe8

Immune profiling of COVID-19 patients has identified numerous alterations in both innate and adaptive immunity. However, whether those changes are specific to SARS-CoV-2 or driven by a general inflammatory response shared across severely ill pneumonia patients remains unknown. Here, we compared the immune profile of severe COVID-19 with non-SARS-CoV-2 pneumonia ICU patients using longitudinal, high-dimensional single-cell spectral cytometry and algorithm-guided analysis. COVID-19 and non-SARS-CoV-2 pneumonia both showed increased emergency myelopoiesis and displayed features of adaptive immune paralysis. However, pathological immune signatures suggestive of T cell exhaustion were exclusive to COVID-19. The integration of single-cell profiling with a predicted binding capacity of SARS-CoV-2-petides to the patients’ HLA profile further linked the COVID-19 immunopathology to impaired virus recognition. Towards clinical translation, circulating NKT cell frequency was identified as a predictive biomarker for patient outcome. Our comparative immune map serves to delineate treatment strategies to interfere with the immunopathologic cascade exclusive to severe COVID-19.

). Compared to COVID-19m, the severe disease was 132 characterized by significantly lower frequencies of CD8 + T cells, coupled with higher 133 frequencies of B cells (Fig. S1D ).

We next combined all cytometry parameters of the surface panel (Table S2A) (Fig. 1C, S1E) . Stratification of the COVID-19 cohort data by sex or age did not 141 reveal marked differences in immune phenotypes (Fig. S1F , S1G).

To uncover the immunological dysregulation of COVID-19s that is distinct from the Table S3 ). Building on the 241 above-described common myeloid features, there were also phenotypic changes within this 242 compartment that were specific to COVID-19s. Specifically, there was significantly lower 243 expression of HLA-DR as well as the co-stimulatory ligand CD86 across antigen presenting 244 cell (APC) subsets, which persisted throughout the duration of our study and were not (Fig. 5B ). This NKT cell reduction was already apparent within the first week after can distinguish severe COVID-19 patients from mild disease with a sensitivity of 100% 264 already at day 0-2 after hospital admission. This finding defines NKT frequency as a 265 powerful predictive biomarker for COVID-19s evolution and furthermore suggesting a role of 266 these cells in the first phase of disease.

In addition to the above-described upregulation of PD-1 predominantly in CD4 + T cells, 268 higher expression of PD-1 by CD4 + EM cells turned out to be a feature unique to 269 (ES vs HAP > 0.4), which positively correlated with severity grade (Fig. 5C, S5B ). 

The protein expression of CD38, another activation marker, across several T cell subsets 279 positively correlated with COVID-19 severity, with the highest significance (p < 0.0001, R 2 = 280 0.24) in CD4 -CD8 -(TCRγδ enriched) T cells (Fig. 5D, S5D ). Furthermore, we observed a 

Although failing to reach the stringent cut-off for being a unique COVID-19s specific feature 287 (ES vs HAP > 0.4), CD161 was also expressed at a significantly lower level on immature 288 and CD56 low CD16 + NK cells in the early phase of severe SARS-CoV-2 related illness 289 compared to mild disease (Fig. S5F) . Here, the kinetics of CD161 expression was low at the 290 beginning of disease with a delayed hyperreactivity in COVID-19s (Fig. S5F ). Further 291 dissecting the NK cell compartment, CD95 expression in the CD56 high NK subset positively 292 correlated with severity of COVID-19 and represents a unique characteristic specific to 293 SARS-CoV-2 infection (Fig. 5F, S5G) . As in the DC compartment described before, the 294 significant and specific reduction of this NK subset supports the Fas-mediated, activation-295 induced apoptosis as the mechanism underlying the shift from effector to immature NK cells 296 (Fig. S5H ).

Regarding the cytokine polarization profile, a reduced production of IFN-γ in CD4 + central 298 memory (CM) T cells was found to be COVID-19s specific and reflects the loss of CD4 + 299 J o u r n a l P r e -p r o o f 19s specific category and diverging from HAP recovered only partly, both in mild and severe compartment (Fig. 5I ).

The recorded myeloid features in COVID-19s were even more pronounced in the HAP 304 patients (Fig. 4G, 4H ). In contrast, several identified COVID-19s specific T and NK cell 305 features were clearly different from what has been observed in HC and HAP (Fig. 5B , 5E, 306 5H, 5J). Taken together, whereas changes in the myeloid compartment are shared across 307 severe RS patients, our differential display approach extracted signatures of T cell Table S5 ). This predicted binding capacity for HLA-A,

HLA-B and HLA-C was further called HLA score 50. Next, we integrated this dataset to our 

In conclusion, we provide a translational path forward based on our differential immune map 357 specific for severe SARS-CoV-2 infection combined with predicted HLA class I binding 358 capacity to SARS-CoV-2 peptides, which can be used to guide therapeutic approaches (Table S2A) . After another washing step, the second 764 surface-antibody staining step (100 µl) was performed for 15 min at 4°C (Table S2A) 

Early Transmission Dynamics in Wuhan, China

Genomic characterisation and epidemiology of 2019 novel coronavirus: 991 implications for virus origins and receptor binding

GM-CSF blockade with 994 mavrilimumab in severe COVID-19 pneumonia and systemic hyperinflammation: a single-995 centre, prospective cohort study

Longitudinal analyses reveal immunological misfiring 998 in severe COVID-19

Long covid could be four different syndromes, review suggests

The end 1002 of gating? An introduction to automated analysis of high dimensional cytometry data

Deep immune profiling of 1006

COVID-19 patients reveals distinct immunotypes with therapeutic implications. Science (80-. 1007 )

Estimating the size of treatment effects: moving 1009 beyond p values

UMAP: Uniform Manifold 1011 Approximation and Projection

UMAP: Uniform Manifold Approximation and 1013 Projection

Pathological inflammation in patients with COVID-19: a 1015 key role for monocytes and macrophages

Cytokine release syndrome in severe COVID-19

CCR2 C COVID-19 severity COVID-19 severity COVID-19 severity COVID-19 severity COVID-19 severity Leukocytes (10^3/µl) Lymphocytes (10^3/µl) Monocytes

Granulocytes (10^3/µl)

Leukocytes (10^3/µl) Lymphocytes (10^3/µl) Monocytes (10^3/µl)

Platelets (10^3/µl)

We thank the patients and blood donors who contributed to this study, and the hospitals at 492 Nantes, Toulouse and Tübingen for sample and data collection. Regarding specifically the **** ****